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Highlights: 
x Peritoneal carcinomatosis pathological features make it suitable cancer for PDT 
x PDT in animal studies showed significant survival increase and tumour regression 
x Intraperitoneal PDT was feasible in human but limited by narrow therapeutic window 
x Poor tolerance of PDT was mainly due to SKRWRVHQVLWLVHUV¶low tumour-selectivity 
x Photoimmunoconjugation LPSURYHG3'7¶VHIILFDF\DQGWROHUDQFHLQDQLPDOVWXGLHV 
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Abstract: 
Background:  
Peritoneal carcinomatosis results when tumour cells implant and grow within the peritoneal 
cavity. Treatment and prognosis vary based on the primary cancer. Although therapy with 
intention-to-cure is offered to selective patients using cytoreductive surgery with 
chemotherapy, the prognosis remains poor for most of the patients. Photodynamic therapy 
(PDT) is a cancer-therapeutic modality where a photosensitiser is administered to patients 
and exerts a cytotoxic effect on cancer cells when excited by light of a specific wavelength. It 
has potential application in the treatment of peritoneal carcinomatosis. 
 
Methods:  
We systematically reviewed the evidence of using PDT to treat peritoneal carcinomatosis in 
both animals and humans (Medline/EMBASE searched in June 2017).  
 
Results:  
Three human and 25 animal studies were included. Phase I and II human trials using first-
generation photosensitisers showed that applying PDT after surgical debulking in patients 
with peritoneal carcinomatosis is feasible with some clinical benefits. The low tumour-
selectivity of the photosensitisers led to significant toxicities mainly capillary leak syndrome 
and bowel perforation. In animal studies, PDT improved survival by 15-300%, compared to 
control groups. PDT led to higher tumour necrosis values (categorical values 0-4 
[4=highest]: PDT 3.4±1.0 vs. control 0.4±0.6, p<0.05) and reduced tumour size (residual 
tumour size is 10% of untreated controls, p<0.001).  
 
Conclusion:  
PDT has potential in treating peritoneal carcinomatosis, but is limited by its narrow 
therapeutic window and possible serious side effects. Recent improvement in tumour-
selectivity and light delivery systems is promising, but further development is needed before 
PDT can be routinely applied for peritoneal carcinomatosis.  
 
Keywords: Photochemotherapy; neoplasms; photosensitizing agents; peritoneum; 
photodynamic therapy; peritoneal carcinomatosis 
 
Words count: 5,509 (without abstract) 
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Introduction 
Peritoneal carcinomatosis describes the dissemination and growth of cancer deposits within 
the peritoneal cavity. These most commonly represent secondary metastases from 
colorectal, ovarian, urogenital, gastric and pancreatic cancers. Less commonly, cancer 
deposits metastasise from melanomas or malignancies of distant organs such as the breast. 
Primary tumours originating from the peritoneum (e.g., peritoneal mesothelioma and primary 
peritoneal carcinoma) are rare1,2.  
 
The peritoneum has a complex anatomy with a large surface area equivalent to that of the 
external body3. Peritoneal cancer deposits can be extensive4 and cover vital intra-abdominal 
structures (e.g., small bowels, liver and great vessels)3. Peritoneal carcinomatosis can occur 
in the absence of haematogenous or lymphatic metastases5, causing local complications, 
including ascites and bowel obstruction4. 
 
The therapeutic modalities and prognosis vary widely depending on the origin of the primary 
cancer. Whilst some patients are treated with intention to cure, most patients have a poor 
prognosis and therapies are aimed at palliative symptom control.  
 
Patients with pseudomyxoma peritonei or appendiceal neoplasia with peritoneal metastases 
can be treated with cytoreductive surgery and heated intraperitoneal chemotherapy with 
reasonable outcomes (median survival 196 months)6. Peritoneal carcinomatosis of ovarian 
origin can be treated with intention to cure in selected patients who are fit for major surgery 
with acceptable perioperative morbidity.7,8 For selected patients, cytoreduction surgery, 
which aims to resect all macroscopic disease, is performed before or after chemotherapy 
(median survival 22-64 months)9. Peritoneal carcinomatosis secondary to gastrointestinal 
cancers (e.g. gastric or colorectal) have a poor prognosis even in the selected patients 
where cytoreductive surgery and heated intraperitoneal chemotherapy is attempted (median 
survival 8 and 7-19 months for gastric and colorectal, respectively)10-12 
 
Photodynamic therapy is a therapeutic anti-cancer modality that has been used to treat 
many cancers, including oesophageal, skin and lung cancers13. A photosensitiser is 
administered that more rapidly accumulates in malignant compared to non-malignant tissue. 
A ground state photosensitiser is activated to a higher energy active triplet state when 
exposed to light of a particular wavelength. Decay of the active triplet state releases energy 
in the form of electrons to generate toxic singlet oxygen (1O2) and reactive oxygen species. 
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These products mediate tumour cell toxicity, microvascular damage14 and  anti-tumour 
immune responses13,15-17. 
 
In 1986, Tochner et al investigated the use of photodynamic therapy in a peritoneal 
carcinomatosis murine model. They reported a high cure rate of 85%18. This encouraged 
further research into the use of photodynamic therapy in peritoneal carcinomatosis over the 
next three decades13. Preliminary evidence suggests that photodynamic therapy might 
improve the outcomes of peritoneal carcinomatosis management and provide an effective 
modality alongside other therapeutic options.  
 
This article is the first attempt to systematically review all existing evidence concerning the 
use of photodynamic therapy in treating peritoneal carcinomatosis. Given the limited 
evidence in human disease, we included animal studies to create an overview of the entire 
knowledge base. 
 
Methods 
Criteria for study inclusion 
Studies 
All original peer-reviewed comparative and non-comparative studies of any type were 
included. Conference proceedings were excluded. 
 
Participants:  
Patients or animal models with peritoneal carcinomatosis of any origin were included. 
Peritoneal carcinomatosis was defined by having more than one intraperitoneal nodule 
(disseminated model). Animal models where only one solid mass was obtained and those 
where seeding was performed outside the peritoneal cavity (e.g., flanks) were excluded. 
 
Interventions 
All studies that used any type of photodynamic therapy, with or without other modalities, to 
treat cancerous nodules within the peritoneum were considered. In vitro studies were 
excluded. 
 
Primary outcomes:  
x Survival 
x Adverse effects 
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Secondary outcomes: 
These outcomes measured the local pathological tumour response to the treatment: 
x Nodule necrosis: this represents the proportion of tumour mass which is found to be 
necrotic. A= mild (<1/3 of the tumour mass), B= moderate (1/3 - 2/3 of the tumour mass), 
C= strong (>2/3 of the tumour mass). 
x Tumour size: in order to estimate the tumour size, some studies used bioluminescence 
imaging which assesses the luciferase activity in cancer cells that stably express 
luciferase. Other studies tagged cancer cells with green florescent protein before 
seeding them into animal models. The fluorescence intensity was used to estimate 
tumour size. 
x Mean percentage of tumour burden: this equals the mean tumour burden of the 
treatment group divided by the mean tumour burden of the control group (mean tumour 
burden per group was calculated by subtracting the weight of organs in a third group of 
healthy animal from the weight of organs in the tumour animal model). 
x Experimental peritoneal cancer index: this index divides the abdominal cavity into four 
quadrants and each quadrant is given a score of 0 to 5 based on the size of tumour in it 
(0: no tumour is visible, 1: tumour is 0 to 0.5 cm, 2: tumour is 0.5 to 1 cm, 3: tumour is 1 
to 2 cm, 4: tumour is 2 to 3 cm, 5: tumour > 3 cm). The results of all four quadrants are 
summated giving an experimental peritoneal cancer index score of 0 to 20. 
x Necrosis value: this is determined by the depth of the necrotic area in the specimen in 
relation to the full tumour thickness (score= 0: no necrosis, score= 1: necrosis up to 33 
%, score= 2: necrosis is 33-66 %, score= 3: necrosis is 66-99 %, score=4: necrosis is 
100%) for each sample of the illuminated peritoneum19. µResponse¶ is defined as having 
a necrosis value of 3 or 4. µ,nsufficient response¶ is defined as having a necrosis value of 
0 to 2. 
 
Search strategy: 
Literature searches were performed in both MEDLINE and EMBASES databases (June 
2017) to identify both animal and human studies investigating the use of photodynamic 
therapy in peritoneal carcinomatosis of any origin. The used search terms were 
(³SKRWRG\QDPLF´ 25 ³SKRWRFKHPRWKHUDS\´ 25 ³SKRWRWKHUDS\´ 25 ³SKRWRUDGLDWLRQ´ OR 
³SKRWRLPPXQRWKHUDS\´ 25 ³IOXRUHVFHQ´) $1' ³SHULWRQH´ LQ DQ\ ILHOG 7KH VHDUFK ZDV
restricted to articles written in English.  
 
Study selection: 
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The selection process was divided into two phases. In the initial phase, the titles and 
abstracts of all citations located through the electronic search were scanned to identify 
potentially relevant articles to the eligibility criteria. The full texts of the relevant articles were 
obtained in the second phase and assessed for inclusion or exclusion. The selection process 
was performed independently by two authors (MQA and GG). Only studies that fulfilled the 
eligibility criteria were included. In cases of disagreement, a consensual decision was made 
IROORZLQJ GLVFXVVLRQ RI WKH IXOO PDQXVFULSW 7KH UHIHUHQFHV RI WKH µUHOHYDQW DUWLFOHV¶ ZHUH
checked for any additional relevant articles. 
 
Risk of bias assessment:  
The risk of bias in the included studies was determined using an assessment tool modified 
from the Cochrane Collaboration assessment tool for interventional studies 20,21. This 
included 10 elements (i. randomisation, ii. concealment of allocation, iii. blinding of 
assessors, iv. sample size calculation, v. statistical model description, vi. description of 
subjects, vii. disclosing financial support, viii. incomplete outcome data, ix. detailed 
description of intervention and x. description of housing and nutrition conditions for animals 
LQSUHFOLQLFDOVWXGLHV7KHDQVZHUVWRWKHDERYHHOHPHQWVZHUHHLWKHUµ\HV¶LIWKHDUHDwas 
ZHOOFRYHUHGLQWKHDUWLFOHRUµQR¶LIthe element was not reported. 
 
Results 
Description of studies  
Figure 1 summarises the process for identifying studies. Twenty eight studies were included 
in this review: three human studies (11 citations)3,22-29 and 25 animal studies18,19,30-52. 
 
Twenty seven studies were excluded. Reasons for exclusion were: non-tumour bearing 
animal model27,53-58, no disseminated peritoneal carcinomatosis model (tumour cells injected 
in the flanks59 or subcutaneously60,61 or only a single intraperitoneal tumour62), no 
photodynamic therapy given (photosensitiser only53,63 or light only64), no useful clinical 
outcomes64-70, conference abstracts (no full texts)71-76 and  mixed populations and 
interventions (results are not broken down by intervention)77. 
 
Clinical data (human): 
Three clinical studies investigated the use photodynamic therapy in human patients with 
peritoneal carcinomatosis (Table 1). 
 
Phase I: 
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In a µSKDVH , WULDO¶ 'H/DQH\ 3,24,27 assessed the feasibility and maximum tolerated 
dose of photodynamic therapy in patients with refractory or recurrent disseminated 
peritoneal carcinomatosis. Fifty four patients underwent debulking surgery with 39 having 
successful cytoreduction (i.e. tumour residual < 5 mm) and additional photodynamic therapy 
using a first generation photosensitiser (dihematoporphyrin ethers). Photodynamic therapy 
was modified, starting with a low dose of photosensitisers and escalating the dose from 1.5 
to 2.5 mg/kg, shortening the injection-to-surgery intervals from 72 to 48 h, and increasing the 
light dose.  
 
Initially, red light (630 nm) at increasing dose of 0.2-3.0 J/cm2 was used alone to illuminate 
the bowel and mesentery. However, due to the observed small bowel oedema and 
perforation, the light source was switched to green light (514 nm; dose 2.5-9.0 J/cm2). 
Additional boosts of red light (dose up to 10-15 J/cm2) or green light (dose up to 5.0-7.5 
J/cm2) were delivered to sites of gross disease on the peritoneum. Dilute lipid emulsion was 
sued to help light scattering within the peritoneal cavity the light. Four photodiodes were 
used to measure the real time dosimetry; three of them were sewn into the parietal 
peritoneum and a fourth one was left as a mobile one. The maximum tolerated dose of 
photodynamic therapy given 48 h after intravenous administration of dihematoporphyrin 
ethers (2.5 mg/kg) was 3.75 J/cm2 of green light with boosts of green light (5.0 to 7.5 J/cm2) 
or red light (10-15 J/cm2) to the sites of gross disease. 
  
No operative or post-operative (within 30 days) mortality was reported. The major 
complications were small bowel perforation (n=3), gastric perforation (n=1) and colo-
cutaneous fistula (n=1). Twenty three patients (59%) developed a pleural effusion, of whom 
six patients needed thoracocentesis. Mild adverse effects included transient mild 
thrombocytopenia (63%), transient insignificant elevated liver enzymes (AST 89%, ALT 
86%) and phototoxicity (15%).  
 
Thirty one patients (80%) had no evidence of disease recurrence at 2-3 months follow up. At 
3-27 months follow up, 9 patients (23%) were disease-free, 21 patients (54%) had recurrent 
tumour and 9 patients (23%) died of progressive disease. The median survival of patients 
who received photodynamic therapy was 30 months. 
 
Phase II: 
Using the tolerated doses revealed by the phase I trial, Hahn et al (2006) 22,23,25,26,29,78,79 
examined the efficacy and toxicities of using photodynamic therapy in a µSKDVH,,WULDO¶One 
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hundred patients with refractory peritoneal carcinomatosis or sarcomatosis, in the absence 
of distant metastases, were recruited. 
 
Photofrin (2.5 mg/kg) was given intravenously to all patients 48h before undergoing a 
debulking surgery. After surgery, patients with residual nodules of <5mm received light 
therapy (n=71). Illumination was with green light for the mesentery and the bowel at a dose 
of 2.5 J/cm2 whilst red light was used to treat the rest of the peritoneal surfaces. Sites of 
gross disease received extra-boost treatment of red light up to 15 J/cm2. Patients were 
instructed to avoid direct light exposure for 30 to 60 days after the operation. 
 
Two patients died post-operatively (n=1 myocardial infarction, n=1 sepsis). The most 
common adverse effect related to photodynamic therapy ZDVµFDSLOODU\OHDNV\QGURPH¶ with 
massive fluid shifts into the abdominal cavity. The average fluid requirement in the first 48h 
after operation was 29.3± 12.4 L. Twenty patients developed grade I or 2 skin 
photosensitisation. Other complications included bowel fistulae and anastomotic leaks (n=4), 
poor wound healing (n=4), and prolonged intubation > 1 day (n=24).  
 
Patients had a median follow up of 51 months. The median disease-free survival and overall 
survival for the patients who underwent photodynamic therapy with cytoreductive surgery 
(n=71) were 3.0 and 22.0 months for ovarian cancer patients (n=23), 3.3 and 13.2 months 
for gastrointestinal cancer patients (n=22) and 4.0 and 21.9 months for sarcoma patients 
(n=26). When all enrolled patients were included (n=100), the results were 2.1 and 20.1 
months for ovarian cancer, 1.8 and 11.1 months for gastrointestinal cancer and 3.7 and 21.9 
months for sarcoma. In patients who only had locoregional recurrence, most of the 
recurrence areas were not previously involved in the gross disease29. 
 
Other trials: 
Wierrani (1997)28 investigated the use of photodynamic therapy in eight patients with 
recurrent gynaecological cancer that metastasised to the peritoneum. All patients had 
previous surgery combined with either chemotherapy (n=6) or radiotherapy (n=2). Six 
patients had cytoreductive surgery combined with photodynamic therapy while two patients 
underwent photodynamic therapy alone. Mesotetrahydroxyphenylchlorin (Foscan®) was 
used as the photosensitiser at an intravenous dose of 0.15 mg/kg 96 h before the operation. 
KTP:YAG pumped laser (652 nm, red light) was delivered at a fluence of 5 J/cm2 using a 
cylindrical diffusing fibre.  
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One patient died 2 days post-operatively with multiple organ failure secondary to cardiac 
insufficiency. Reported adverse effects included grade 1 and 2 cutaneous burns (3 patients) 
and prolonged ileus. Disease-free survival was 17.6 (0-32) months. 
 
Preclinical data (animal models) 
1. Photodynamic therapy versus control: 
1.1 Survival 
Eleven animal studies 18,31,32,34-36,42,45,47,49,80 compared the overall survival of animals treated 
with photodynamic therapy with those left untreated (table 2). The studies used different 
animal models, photosensitisers and light doses. They all found a significant prolongation of 
survival of animals treated with photodynamic therapy (between 15% and 300%) in 
comparison with those left untreated (figure 2).  
 
Song et al36 combined cytoreductive surgery with photodynamic therapy and compared this 
with cytoreductive surgery alone in a rat ovarian cancer model. Adding photodynamic 
therapy to cytoreductive surgery led to significant improvement in animal survival in 
comparison with cytoreductive surgery alone (cytoreduction surgery + photodynamic therapy 
45 days vs. cytoreductive surgery alone 15 days, p<0.01). Similar results were shown by 
Yokoyama et al49 although the difference did not reach statistical significance (cytoreductive 
surgery + photodynamic therapy 46 days vs. cytoreductive alone 36 days, p=0.08). 
 
1.2 Toxicity 
Mroz et al 42 used Fullerene BB4 (5mg/kg intraperitoneally) in mice with colonic cancer 
peritoneal carcinomatosis.  A fluence of 100 J/cm2 was used when illuminating the 
peritoneum with either of three lights (white, green or red). The authors reported death in all 
mice in the photodynamic therapy group illuminated with red light. No mortality occurred 
when red light was used without the photosensitiser. The other photodynamic therapy 
groups illuminated with white or green light experienced no adverse effects. 
 
Kishi et al 39 used Talaporfin (10 mg/kg intraperitoneally) in mice with gastric cancer 
peritoneal carcinomatosis. The authors compared different illumination regimens using 
fluences of 2, 5 or 10 J/cm2 either 2 or 4 h after injecting the photosensitiser. There was 
increasing oedema formation in the small bowel wall as the dose increased from 2 to 10 
J/cm2 irrespective of whether the illumination occurred 2 oU KDIWHU WKHSKRWRVHQVLWLVHU¶V
injection. Intestinal ischaemic changes were noted in both the 5 and 10 J/cm2 groups which 
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were illuminated 2 h post injection, but not in the groups illuminated 4 h post injection. All 
mice (n=5) treated with 2 J/cm2 at 2 h interval died 3 days post photodynamic therapy (due 
to intestinal perforation) whilst all those treated with 2 J/cm2 4 h post injection survived with 
no complications until 30 days after the photodynamic therapy. The authors concluded that 
laser dose of 2 J/cm2 and a 4 h interval between Talaporfin administration and laser 
treatment is the optimal safest treatment. 
 
1.3 Pathological response: 
Seventeen animal studies 32-35,37-41,43-48,52,81 investigated the peritoneal tumour response 
when treated with photodynamic therapy as compared to controls (table 3).  
 
The studies show significant pathological response of the tumour in response to 
photodynamic therapy. Animal groups treated with photodynamic therapy had more necrosis 
in the tumour area (70% ± 13% versus 33% ± 8%)40, less weight of the residual carcinoma 
(34 ± 14 µg versus 379 ± 65 µg, p <0.001)32, and higher necrosis values (3.4 ± 1.0 versus 
0.4 ± 0.6, p <0.05)37 in comparison to controls. The µmean percentage of tumour burden¶ in 
the photodynamic therapy group was almost a third that of the control group (38%, 95% 
confidence interval 29%-47%, p <0.001)35. 
 
2. Synergistic effect of combined therapy: 
2.1 Anti-epidermal growth factor receptor 
Epidermal growth factor receptor is a receptor that promotes disproportionate cell 
proliferation and is associated with poor prognosis of a variety of cancers82. Cell cycle arrest 
is induced by competitive binding of the monoclonal antibody Cetuximab with native ligand 
epidermal growth factor for epidermal growth factor receptor binding sites83,84. 
 
Del Carmen et al 35 examined the efficacy of combining immunotherapy with photodynamic 
therapy.  Human epithelial ovarian cancer cells were seeded into the peritoneum of mice. 
The anti-epidermal growth factor receptor group received 0.5 mg of Cetuximab 
intraperitoneally on days 11, 14, 17 and 19 after tumour inoculation (2 mg per mouse). The 
photodynamic therapy group received 0.25 mg/kg of liposomal benzoporphyrin derivative 
monoacid intraperitoneally.  Ninety minutes after injecting the photosensitiser, the 
peritoneum of the mouse was illuminated with red light (690 nm) at a fluence of 20 J/cm2. 
The combination group received both treatments (cetuximab and photodynamic therapy). 
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The median survival for the combined group was 80 days, which was double the median 
survival in photodynamic therapy group (38 days). Both the combined group and the 
photodynamic therapy group showed significant improvement in survival in comparison with 
the no-treatment group (28 days), p <0.001 and p= 0.01, respectively. Survival in the 
cetuximab group was 26 days and not different from the no-treatment group. The mean 
percentage of tumour burden when using the combined therapy was significantly lower than 
that reported in the individual treatment groups (combined modality: 10%, 95% confidence 
interval 2-17%, photodynamic therapy: 38%, 95% confidence interval 29-47%, cetuximab: 
67%, 95% confidence interval 59-74%, p <0.001). 
 
2.2 Photoimmunoconjugate:  
Many investigators have tried to improve the selectivity of photosensitisers by conjugating 
them with antibodies directed against antigens specific to cancer cells forming 
photoimmunoconjugates.  
 
In 1996, Molpus et al 34 conjugated the photosensitiser Chlorinee6 with OC125. OC125 is a 
monoclonal antibody that recognises CA-125, a cell surface antigen highly expressed by 
ovarian cancer cells 85. The resulting photoimmunoconjugate could be produced with either a 
cationic or anionic charge. A mouse model of peritoneal carcinomatosis from human ovarian 
cancer was used. Mice were injected intraperitoneally with either chlorinee6 (n=10), anionic 
photoimmunoconjugate (n=16), cationic photoimmunoconjugate (n=19) or left untreated 
(n=12). Illumination using red light (650nm, dose 25 J/mice) was 3 h after injecting the 
photosensitiser or its functionalised form.  
 
The median survival was found to be higher in the cationic photoimmunoconjugate group (41 
days) in comparison with the anionic photoimmunoconjugate group (37 days, p <0.05), the 
chlorinee6 group (34.5 days, p <0.05) and the control group (35 days, p <0.01). A highly 
significant decrease in the residual intraperitoneal tumour was seen in all three treatment 
groups in comparison with the control group; the greatest effect was found in the cationic 
photoimmunoconjugate group (cationic photoimmunoconjugate 33± 20mg, anionic 
photoimmunoconjugate 73 ± 29 mg, chlorine e6 59 ± 18 mg, control 330 ± 109 mg, p 
<0.0001). 
 
Goff et al (1996) 31 investigated the use of photoimmunoconjugate (chlorine e6 + OC125) in a 
murine disseminated ovarian cancer model. Mice in the photoimmunoconjugate group 
survived significantly longer than those in the control group (p<0.001). However, there was 
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no µChlorinee6-mediated photodynamic therapy only¶ group to assess the additive-effect of 
photoimmunoconjugation. 
 
More recently, Sato (2014)44 and (2015)46 used a photoimmunoconjugate (tra-IR700) which 
comprised a photosensitising agent (IR-700) conjugated to Trastuzumab (a monoclonal 
antibody against HER2 receptors). A HER2-expressing cancer cell line (N87-GFP44, SKOV-
Luc46) was used to establish a disseminated peritoneal carcinomatosis mouse model. 
Significant reduction in the tumour size was reported following photoimmunoconjugate-
mediated photodynamic therapy in comparison with the no-treatment group44,46,47. Harada 
(2016)48 conjugated IR-700 with galactosyl serum albumin, which ELQGV WR ȕ-D-galactose 
receptors. An ovarian cancer cell line (SHIN3), which overexpresses D-galactose receptors, 
was used. A significant reduction in tumour size was reported in the photoimmunoconjugate 
group in comparison with control groups (p<0.05).  
 
Ishida (2016)47 investigated improving the effect of tra-IR700 mediated photodynamic 
therapy by increasing the expression of the antigen (HER-2) in the ovarian cancer cells. A 
HER-2 negative cancer cell line (MKN45-Luc) was used in their animal model. Adenoviral 
vector, which carries the HER2-extracellular domain gene, was used to induce exogenous 
HER2-extracellular domain overexpression on the HER2-negative cancer cell membranes 
and sensitise them to Trastuzumab. Adding the adenoviral vector to the 
photoimmunoconjugate led to a significant reduction in the residual tumour weight (HER-2 
adenovirus vector + photoimmunoconjugate-mediated photodynamic therapy: 0.50± 0.06 g, 
photoimmunoconjugate-mediate photodynamic therapy alone: 1.10± 0.29 g, no treatment: 
1.32± 0.58 g, p<0.05). 
 
2.3 Anti-angiogenesis 
Piatrouskaya et al 40 argued that the release of pro-angiogenic mediators, particularly 
vascular endothelial growth factor, following photodynamic therapy could compromise its 
cytotoxic effect by allowing the tumour to restore its microvasculature. They assessed the 
early tumour response after combining photodynamic therapy with an anti-angiogenesis 
treatment (Bevacizumab) in a peritoneal sarcomatosis rat model. Animals were divided into 
four groups: the photodynamic therapy group (n=5) which received Fotolon (intravenous 2.5 
mg/kg) and were illuminated with a laser (670 nm) via a laparotomy approach (5 J/cm2 with 
boost treatment up to 100 J/cm2 for gross disease sites); the anti-angiogenesis group (n=5) 
which received Bevacizumab (intravenous 15 mg/kg); the combined treatment group (n=5) 
which received both modalities; and the control group (n=3) which received no treatment.  
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Four days after the intervention, there was a significant increase in the µnecrosis to tumour 
percentage¶ in the combined treatment group (90% ± 7%) in comparison with the 
photodynamic therapy group (70% ± 13%), the anti-angiogenesis group (42 % ± 11 %) and 
the control group (33 % ± 8 %), p = 0.000. 
 
3. Photodynamic therapy versus chemotherapy: 
Raue et al 41 compared different regimens of chemotherapy and photodynamic therapy in a 
rat model with peritoneal malignancy of colonic origin. Animals were randomly divided into 
six groups of 15 animals. Group 1 received no treatment, Group 2 had cytoreductive 
surgery, Groups 3 to 6 had cytoreductive surgery followed by either hyperthermic 
intraoperative peritoneal chemotherapy with mitomycin 15 mg/m2 (Groups 3), intraperitoneal 
taurolin 0.5% (Group 4), hyperthermic intraoperative peritoneal chemotherapy with 
gemcitabine 24 mg/kg (Group 5), or protoporphyrin IX-mediated photodynamic therapy 
(intravenous 5-aminolevulinic acid 150mg/kg 6 h pre-operatively, illumination with red light 
(630 nm), power 3 watts, duration 2 x 10 min) (Group 6).  
 
All treatment groups (Groups 2 - 6) had significantly lower tumour weight and experimental 
peritoneal cancer index in comparison with the control group. The experimental peritoneal 
cancer index was lower in the mitomycin group (median 4, range 0-14) in comparison with 
the photodynamic therapy group at the parameters used (median 6, range 0-20) (p =0.03). 
However, no significant difference was found in the residual tumour weight between these 
two groups. Applying protoporphyrin IX-mediated photodynamic therapy at this same dose 
and timing with cytoreductive surgery did not lead to significant decrease in tumour weight 
when compared with cytoreductive surgery alone (median 0.3, range 0-20 versus median 
1.4, range 0- 21.5). 
 
4. Continuous versus fractionated illumination for photodynamic therapy: 
Ascencio et al51 compared two methods of illumination for photodynamic therapy: continuous 
and fractionated. The authors injected hexaminolaevulinate intraperitoneally at a dose of 100 
mg/kg in rats with peritoneal carcinomatosis of ovarian origin. Illumination using green light 
(532 nm, 30mW/cm2) was performed 4 h after the photosensitiser¶V injection. The rats were 
divided into two groups: the continuous-1 group (n=20), which received a continuous 
illumination of a total fluence of 45 J/cm2, and the fractionated group (n=16), which received 
a fractionated illumination (on for 120 sec then off for 60 sec) until reaching a fluence of 30 
14 
 
J/cm2 (i.e., total illumination duration equals that of the continuous group). Biopsies were 
taken 24 h after treatment to assess the pathological response. The mean necrosis value 
was significantly higher in the fractionated light group (3.7 ± 0.7) in comparison to the 
continuously applied light group (3.1 ± 0.9), p <0.05. 
 
In another experiment by the same group50, a similar protocol was used but with the addition 
of a third group (continuous-2) which received continuous illumination at a reduced fluence 
of 30 J/cm2 (similar overall dose to the fractionated group). Tumour destruction assessed by 
the depth of necrosis was higher using the fractionated illumination in comparison with 
continuous illumination applications (fractionated: 213 ± 113 µm vs. continuous-1: 154 ± 133 
µm versus continuous-2: 171 ± 155 µm, p<0.05). Although no significant difference was 
found in the mean necrosis value between the three different methods of illumination, the full 
necrosis (necrosis value of 4) rate was significantly higher in the fractionated group 
(fractionated: 50 % versus continuous-1: 30 % versus continuous-2: 10 %, p < 0.0001).  
 
Discussion 
Residual peritoneal metastases after cytoreductive surgery remain a surgical challenge and 
a significant contributor to cancer recurrence86. The pathophysiological characteristics of 
peritoneal carcinomatosis, namely disseminated nodules localised to the peritoneum with 
little penetration of the underlying structures87, make it an ideal form of cancer to treat with 
photodynamic therapy. The effects of photodynamic therapy are limited by tissue light 
penetration, making it most effective for surface malignancies. Visible light is needed to 
activate  photosensitisers that are taken up or are in close proximity to cells14. Therefore, the 
depth of the therapy can be controlled by using different wavelengths79. This facilitates 
treating cancerous nodules that have spread over the large area of the peritoneum with 
limited toxicity to deeper structures, such as the intestines3,78. 
 
Summary of results: 
In this systemic review, we explored the use of photodynamic therapy for the treatment of 
peritoneal carcinomatosis highlighting the pros and cons of its use in isolation and as a 
combined therapy. This review includes three human and twenty five animal studies. Animal 
studies have shown promising results with treated animals surviving 15 - 300% longer than 
control groups. Photodynamic therapy was shown to double the extent of tumour necrosis 
and reduce tumour size by up to 90%. 
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Phase I and II human trials have shown that applying photodynamic therapy after surgical 
debulking of peritoneal carcinomatosis is feasible3,78. Some benefit in terms of slightly 
prolonged survival have been described, but did not lead to long-term tumour control. The 
toxicity induced by intraperitoneal photodynamic therapy was also significant. Post-therapy 
capillary leak syndrome characterised by excessive fluid shifts and bowel perforation were 
the main adverse effects23,78.  
 
Interpretation of the findings of these Phase I and II clinical trials, including the efficacy and 
toxicity profiles of photodynamic therapy, is limited by certain drawbacks. Firstly, the authors 
included a heterogeneous population of patients with peritoneal sarcomatosis and 
carcinomatosis of different origin. Secondly, all the included patients had poor prognosis and 
failed to respond to first line treatments including surgical debulking and chemotherapy. 
Future trials should ideally focus on selected populations with intention to cure. Thirdly, the 
included patients received a suboptimal incomplete macroscopic cytoreductive surgery 
(gross residual disease < 5mm). Current practice emphasises the importance of complete 
gross disease debulking which has been IRXQGWROHDGWRVLJQLILFDQWLPSURYHPHQWLQSDWLHQW¶V
prognosis in comparison with incomplete resection.1 Fourthly, nonspecific first generation 
photosensitizers were used in the studies causing significant toxicities. Newer, more cancer-
specific photosensitisers have since been developed. 
 
Current challenges of photodynamic therapy and future directions: 
A photosensitiser, molecular oxygen, and activating light are needed for photodynamic 
therapy. Controlling the adverse effects might be managed by manipulating the activating 
light, the available molecular oxygen and/or the tumour selectivity of the photosensitiser and 
photosensitising agents. The use of the less penetrating green light appears to reduce the 
risk of bowel perforation in comparison to more penetrating red light3,42. However, the trade-
off is that green light is less effective for more invasive cancers, with greater risk of 
incomplete cancer treatment and recurrence. 
 
Only first generation photosensitisers have been evaluated in patients with peritoneal 
carcinomatosis in phase I and II clinical trials3,28,78. One Phase II trial, which was undertaken 
more than a decade ago, showed low tumour-to-normal tissue selectivity ratios for the 
photosensitiser (Photofrin) (tumour-to-normal ratio =0.9 and 0.5 for the small and large 
bowels)25. This low tumour selectivity of Photofrin is attributed to its significant toxicities. In 
addition, Photofrin¶V prolonged retention in tissues, such as the skin, causes skin 
phototoxicity.25  
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Since Hahn et al (2006) report their phase II clinical trial25, significant pre-clinical research 
has been undertaken to improve the tumour-selectivity photosensitisers. Second-generation 
photosensitisers (e.g., meta-tetrahydroxyphenyl chlorin) have been tested in peritoneal 
carcinomatosis animal models and shown to have better tumour-selectivity and shorter in 
vivo retention time. This has improved the therapeutic window and reduced the associated 
phototoxicity33-35,41,43. Integrating targeted molecular therapy into photodynamic therapy 
holds strong clinical potential and has attracted recent attention13. Photosensitisers have 
been functionalised by conjugating them to tumour-specific antibodies, forming 
photoimmunoconjugates. This review suggests that efficacy can be improved by using 
photoimmunoconjugates in comparison with photodynamic therapy only in animal 
models31,34,44,48,69.  This strategy warrants further investigation. 
 
Another area for further study is the potential synergistic effect between photodynamic 
therapy and other anti-cancer treatments. This might allow the doses of photodynamic 
therapy to be reduced whilst retaining the same anti-cancer efficacy. Animal studies have 
shown an improved effect of photodynamic therapy when combined with anti-epidermal 
growth factor receptor 34,35 and anti-angiogenesis 40 agents. 
 
Although a significant decrease in tumour burden has been noted following intraperitoneal 
photodynamic therapy in animals, survival advantage was limited32. This suggests regrowth 
of tumour nodules that escaped photodynamic therapy or were incompletely treated.  
 
Delivering the activating light to allow photodynamic therapy to uniformly treat all potential 
peritoneal surfaces is challenging3,78. The peritoneal surface is a large and complex 
structure. Light delivery to hidden surfaces (e.g., mesentery surface, subhepatic, 
subdiaphragmatic and inter-loop surfaces) is difficult and necessitates moving organs to 
ensure adequate light exposure. Lipid emulsion (Intralipid) was used by Hahn et al and 
placed in the abdominal cavity to help scatter light, reduce shadowing and permit more 
homogenous light delivery to the intra-abdominal organs.88 There is currently no 
commercially available hardware to deliver light within the abdomen. 
 
Interestingly, repeating photodynamic therapy might reduce the risk of tumour recurrence 
with no accumulative toxicity, hypersensitivity or resistance17. This requires repeat access to 
the peritoneal cavity, which might not be practical. Implantable intra-abdominal light sources 
and light scattering solutions could potentially allow repeat photodynamic therapy.  
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As efforts to develop this promising therapeutic modality continue, one of the main 
challenges is the numerous variables which need to be controlled. The studies included in 
this review have used different photosensitisers, drug concentrations, drug-to-light intervals, 
light sources, wavelengths, light fluences and illumination times. This, in addition to the 
different outcomes used to report the results, made it difficult to draw clear conclusions. 
 
Limitations and risk of bias assessment: 
This review is limited by the type of studies included. Whilst the review included a 
reasonable number of studies (n=28), the average sample size was relatively small and 
none of the sample sizes were based on pre-study power calculation. In addition, animal 
models do not always replicate the human experience because of the biological differences 
and any extrapolation from the animal literature needs to be with caution. 
 
There were no concerns about the delivery of the 3 clinical trials. However, the grade of 
evidence was low considering their non-comparative design. Animal studies were scored 
medium in the quality assessment tool (average score= 5.7/10). The main drawback with 
most study designs was the absence of a pre-defined power calculation and the presence of 
selection and performance biases (e.g. randomisation, concealment of allocation and 
blinding of assessors). 
 
Conclusion: 
Photodynamic therapy has efficacy and translational applicability for the treatment of 
peritoneal carcinomatosis. Animal studies of photodynamic therapy have shown promising 
results, but human trials have revealed a narrow therapeutic index that limits its present 
clinical application.  
 
Developing more tumour-selective photosensitisers, combining photodynamic therapy with 
targeting agents and improving light delivery techniques could enhance its therapeutic 
potential. These issues need to be addressed before photodynamic therapy can be 
established within the current management strategy of peritoneal carcinomatosis. 
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Figures: 
Figure 1. Chart flow of search strategy and identification of studies 
Figure 2. Photodynamic therapy versus control in animal models (outcome: survival/days) 
*Both arms had cytoreductive surgery. IP= intra-peritoneal, BB4= N-methylpyrrolidinium-
fullerene, HMME= hematoporphyrin monomethyl ether, BPD-MA= benzoporphyrin 
derivative-mono acid, CMA-OC125= Chlorin e6 monoethylendiamine monamide conjugated 
with OC125. 
24 
 
 
 
 
 
 
 
25 
 
Tables: 
 
Table 1.  Photodynamic therapy for peritoneal carcinomatosis: human clinical trials 
Study Participants  Intervention Survival Toxicity 
Phase I  
Delaney 
19931-3 
USA 
39 patients with 
refractory 
disease, no 
metastases 
outside 
peritoneum 
DHE iv. 1.5- 2.5 
mg/kg 48-72 h 
before CS. If PC 
UHVLGXDOPP
light therapy given 
(red ± green light). 
At potential follow up of 3.8-
43.1 months (median 22.1) 
30/39 (77%) of patients were 
alive and 9/39 (23%) were 
disease-free. 
Small bowel and gastric 
perforations, prolonged 
intubation (7-9 days), colo-
cutaneous fistula, pleural 
effusion, cutaneous 
phototoxicity, transient 
deranged liver function. 
Phase II  
Hahn 2006 
4-10
 
USA 
100 patients 
with refractory 
disease, no 
metastases 
outside 
peritoneum 
Photofrin (DHE) 
2.5 mg/kg i.v 48h 
before CS. If PC 
UHVLGXDOPP
light therapy given 
(red ± green light). 
Median disease-free survival 
and overall survival by strata 
were ovarian (n=33) 2.1 and 
20.1 months; GI (n=37) 1.8 
and 11.1 months, sarcoma 
(n=30) 3.7 and 21.9 months. 
Capillary leak syndrome, 
ARDS, fistulae or 
anastomotic leak, prolonged 
ileus and phototoxicity 
Wierrani 
199711  
Austria 
8 patients with 
recurrent 
gynaecological 
cancer  
m-THPC i.v 96 h 
pre-CS (0.15 
mg/kg), red light. 
Disease-free survival: 17.6 
months (range 0-32 months) 
1 death post operative (heart 
failure). Cutaneous burns 
and  ileus 
DHE= dihematoporphyrin ethers, m-THPC= Mesotetrahydroxyphenylchlorin, CS= cytoreductive surgery, PC= 
peritoneal carcinomatosis, GI= gastrointestinal 
 
Table 2.   Photodynamic therapy for peritoneal carcinomatosis: animal studies (primary outcomes: survival 
& toxicity)  
Stud
y 
Animal
,  
Cancer 
type 
(cells) 
Photose
nsitiser, 
Other 
interven
tions 
Ener
gy 
flue
nce 
Inter
val 
(hou
r) 
Lig
ht 
typ
e 
Survival Impro
ved 
survi
val  
Toxi
city 
26 
 
Ishida 
2016 
1
 USA 
Mice,  
Gastric 
(MKN4
5-
*Luc), 
HER-2 
negativ
e 
Tra-
IR700 
(80 µg 
i.p) 
AD= 
Ad/HER
2-ECD 
(1x108 
pfu) 
injected 
i.p 5 
days 
post 
MKN45-
Luc 
injection. 
50 
J/cm
2
 
24 h  
 
Singl
e or 
repe
ated 
cours
es 
NIR 
690
nm 
Survival, n=5 each group: 
[AD+PDT]> Other groups, (p 
<0.05, log-rank test) 
 
Survival at 50 days: 
[AD+PDT] once = 60%,  
[AD+PDT] treatment repeated x3= 
60% 
[PDT] once= 20% 
[PDT] treatment repeated x3= 25% 
[no treatment]= 0% 
  
Yoko
yama 
20162  
Japan 
Rats, 
Ovaria
n 
(DISS) 
5-ALA 
methyl 
ester 
250mg/k
g i.p 
CA= 
Clofibric 
acid. 
9,000 
ppm 
orally 
daily. 
DS= 
Debulkin
g 
surgery 
90 
J/cm
2
 
 600 
nm 
Survival, n=5 each group: 
Control= 22 days, PDT alone= 33 
days, DS alone= 36 days, 
DS+PDT= 46 days, DS+PDT+CA= 
53 days. 
 
  
Tsuji
moto 
20143 
Japan 
Mice, 
Gastric 
(MKN4
5-*Luc) 
ICGm: 
100µL 
(281µm
ol). 
 
ICGs: 
100µL 
(281µm
ol) 
500 
P:»
cm2 
for 
1,00
0 
sec 
(500 
J 
»cm2) 
 808 
nm 
lase
r 
dio
de 
Survival (n=8 each group) 
ICGm vs. ICGs: 32 vs. 17 days (p < 
0.05) 
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Mroz 
2011 
4
 USA 
Mice, 
Colon 
(CT26) 
BB4, 
5mg/kg 
i.p 
100 
J/cm
2
 
24 h 
(singl
e) 
 
Red  
Whi
te  
Gre
en  
PDT (n=10) vs. Control (n=10):  
   White: 27 vs. 20 days, sig  
   Green: 23 vs. 20 days, sig 
(p=0.02).  
 
35% 
15% 
Red 
light 
led 
to 
deat
h in 
2-3 
days
,  
   3 h 
(singl
e) 
   White: 24 vs. 20 days, sig 
(p<0.01)  
   Green: no significant difference. 
20% 
Song 
2007 
5
 
China 
Rats 
Ovary 
(NuTu -
19) 
HMME  
10mg/kg 
i.p  
50 
J/cm
2
 
3h, 
(singl
e)  
Red  CS +PDT (n=9): 45 days (CI 95% 
1-89) 
CS+ laser alone: 19 days (CI 95% 
14-25)  
CS alone (n=8): 15 days (CI 95% 
7-23), p< 0.01.  
 
236% 
300% 
Non
e 
del 
Carm
en 
20056 
USA  
Mice 
Ovary 
(NIH:O
VCAR-
5) 
BPD  
0.25 
mg/kg 
i.p  
20 
J/cm
2
 
1.5 h 
(singl
e) 
Red  PDT (n=10) vs. Control (n=10):  
36 (IQR 32-90) vs. 28 (IQR 21-31), 
p= 0.01. 
29% Non
e  
Molpu
s 
20007 
USA 
Mice  
Ovary 
(NIH:O
VCAR-
5) 
Ce6-
OC125 
(PIC) 
1mg/kg 
i.p  
25 
J/cm
2 
3 h 
(repe
ated 
x3) 
Red Cationic PIC (n=19) vs. anionic PIC 
(n=16) vs. free Ce6 (n=10) vs 
control (n=11): 
41 vs. 37 vs. 34.5 vs. 35 days 
 
  
Molpu
s 
19968 
USA  
Mice 
Ovary 
(NIH:O
VCAR-
5) 
BPD-MA  
0.25-2.0 
mg/kg 
i.p  
20 
J/cm
2
 
1.5 h 
(repe
ated) 
Red  Advanced disease groups (5-9 
courses): 
PDT (n=11) vs. control (n=9): 57 
vs. 47 days, p <0.05.  
Minimal disease groups ( 3-5 
courses): 
PDT (n=?), vs. control (n=?): 57 vs. 
43 days, p <0.05.  
21% 
 
 
33% 
Non
e  
Goff 
1996 
9
 USA  
Mice 
Ovary 
(NIH:O
VCAR-
3) 
Ce6-
OC125 
(PIC) 
0.5mg/k
g 
 
10-
75 
J/cm
2
 
24 h 
(repe
ated) 
Red  3-4 courses separated by 48h 
PDT 4 courses (n=12) vs. PDT 3 
courses (n=10), vs. control (n=18):  
58 vs. 47.5 vs. 38.5 days, log-rank 
test p<0.001.  
51% Non
e  
Toch
ner 
1986 
10
 
USA 
Mice 
Malign
ant 
Terato
ma 
HPD 
(Photofri
n) 
10mg/kg 
i.p  
 2 h 
(repe
ated)  
Gre
en  
4 courses separated by 48h: 
All controls died within 25 days. 
PDT group: 17/20 (85%) survival at 
25 days. These were disease free 
at 11 months.  
 Non
e  
28 
 
 
Toch
ner 
1985 
11
 
USA 
Mice 
Embry
onal 
ovary 
carcino
ma  
HPD 
(Photofri
n) 50 
mg/kg 
i.p 
 2 h Gre
en 
All controls died before day 23.  
1 Course PDT (day 9): 8/32 (25%) 
died before day 23, 25/32 (78%) 
died before day 34, 1/32 (3%) lived 
> 90 days (cured).  
2 courses of PDT (day 9 and 15): 
6/15 (40%) lived > 90 days (cured) 
 Deat
h 
due 
to 
bow
el 
perfo
ratio
n 
*Luc= luciferases expressing cancer cells. Tra-IR700= IR Dye 700 DX NHS ester conjugated to 
trastuzumab (anti-HER2), Ad/HER2-ECD= adenovirus transduction of HER-2 extracellular domain gene 
into HER-2 negative gastric cancer cells. ICGm= indocyanine green loaded lactosomes, ICGs= 
indocyanine green solution. IP= intra-peritoneal, CS= cytoreductive surgery, IQR= interquartile range, 
BB4= N-methylpyrrolidinium-fullerene, HMME= hematoporphyrin monomethyl ether, BPD-MA= 
benzoporphyrin derivative-mono acid, Ce6-OC125= Chlorin e6 conjugated with OC125, PIC= 
Photoimmunoconjugate, HPD= KDHPDWRSRUSK\ULQGHULYDWLYHIn cremophor micelles. 
Table 3.   Photodynamic therapy for peritoneal carcinomatosis: animal studies (secondary outcomes: pathological local 
response)  
Study Animal & 
Cancer 
Photosensitise
r (PS) 
Energy Interval 
(h) from 
PS 
Light 
type 
Pathological response 
Kato 
20171 
Japan 
Mice, 
pancreatic 
(AsPC1/luc) 
Mal3-chlorin 
1.25 mmol/kg 
i.p 
Talaporfin 1.25 
mmol/kg i.p 
 
13.9 
J/cm2 
Two 
courses 
(day 0, 
day 7) 
660 
nm   
Tumour size, indicated by BLI (n=7 each 
group): 
   Mal3-chlorin vs. control (p= 0.036) 
   Mal3-chlorin vs talaporfin (p=0.074, ns) 
Ascites volume (n=7 each group): 
   Mal3-chlorin vs. control (p= 0.066, ns) 
   Mal3-chlorin vs talaporfin (p=0.159, ns) 
Ishida 
2016 2 
Japan 
Mice,  
Gastric 
(MKN45-
*Luc), HER-
2 negative 
Tra-IR700 (PIC) 
80µg i.p 
 
AD= Ad/HER2-
ECD injected i.p 
5 days post 
MKN45-Luc 
injection. 
50 J/cm2 24 h  
 
Single 
course or 
repeated 
courses 
NIR 
690nm 
Tumour weight [g], n=4 each group: 
[no treatment]= 1.32 േ 0.58  
[PDT alone]= 1.10േ 0.29  
[AD+PDT] = 0.50േ0.06, p< 0.05 
 
Harada 
20163 
USA 
Mice, 
ovarian 
(SHIN3) 
overexpres
ses D-
galactose 
receptors 
GSA-IR700 
(PIC) 25µg i.p 
100 
J/cm2 
(500 
mW/cm2, 
200 sec) 
Repeate
d daily 
for 3 
days 
NIR  Tumour size, indicated by BLI (n=5 each 
group): 
Significant reduction in PDT group in day 2 
(p<0.01), day 3 (p=0.044), day 6 (p=0.049) 
and day 7 (0.042) in comparison with other 
control groups (no treatment, NIR light only; 
GSA-IR700 only).  
 
No significant therapeutic effect in control 
groups. 
Sato 
20154 
USA 
Mice, 
Ovarian 
(SKOV-
*Luc) 
Tra-IR700 (PIC) 
100µg i.v 
50J/cm2 
on day1 
 
100J/cm2
on day2 
 NIR Tumour size, indicated by BLI (n=6 each 
group): Day 7 post PDT 
PDT vs. NIR light alone (p= 0.026) 
PDT vs. no treatment (p= 0.004) 
 
Tumour size, indicated by BLI (n=6 each 
group): Day 14 post-PDT 
PDT vs. NIR light alone (p= 0.033) 
PDT vs. no treatment (p= 0.017) 
PDT vs. tra-IR700 alone (p= 0.013)  
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Sato 
20145 
USA 
Mice  
Gastric 
(N87-GFP),  
HER2 +ve 
Tra-IR700 (PIC)  
100µg i.v 
50J/cm2 
on day1  
 
100J/cm2 
on day2 
 NIR Tumour size (indicated by GFP 
fluorescence intensity, n=5 each group): 
PDT < no treatment (p= 0.049) 
PDT < NIR light alone (p= 0.030) 
PDT < tra-IR700 alone (p= 0.036) 
Tsujimoto 
20146 
Japan 
Mice, 
Gastric 
(MKN45- 
*Luc) 
ICGm: 100µL 
(281µmol). 
 
ICGs: 100µL 
(281µmol) 
500 
P:»FP2 
for 1,000 
sec (500 
-»FP2) 
 808 
nm 
laser 
diode 
Total weight of tumour nodules (n=5 
each group): 
ICGm (1.5 g) vs. ICGs (1.0 g), p< 0.05 
 
Total number of residual nodules: 
ICGm (26) vs. ICGs (30), non-significant 
Hino 2013 
7
 Japan 
Mice 
Gastric 
(MKN-45) 
5-ALA 250 
mg/kg 
4.5 J/cm2 5 Violet 
Green 
Red 
6WURQJQRGXOHV¶QHFURVLV (necrosis >2/3): 
23% (violet**) vs. 17% (green**) vs. 7% 
(red*) vs. 1% (control), **p <0.01, *p <0.05. 
Raue  
20108 
Germany 
 
Rats 
Colonic 
(DHD/K12/
TRb) 
5-ALA 150 
mg/kg i.v 
? 6 h Red ePCI: CS+PDT (n=15) vs. CS alone (n=15): 
6 (0-20) vs. 9(0-20), non-sig difference. 
Piatrouska
ya 2010 9 
Belarus 
Rats 
Sarcoma 
(M-1) 
Fotolon 2.5 
mg/kg i.v 
? ? ? % of necrosis to tumour area:  
PDT (n=5) vs. control (n=3): 70% ± 13% vs. 
33% ± 8% 
Kishi 
201010  
Japan 
Mice 
GastricMK
N-45 
Talaporfin 
10mg/kg i.p 
 
 
2, 5, 10 
J/cm2 
 
 
2 h 
 
Strong nodule necrosis (necrosis > 2/3): 
2 J/cm2 vs. 5J/cm2 vs. 10  J/cm2 
53%, 43%, 64% 
   2, 5, 10  
J/cm2 
4 h  21%, 26%, 26% 
Estevez 
201011 
Rats Ovary 
(NuTu-19) 
HAL 100mg/kg 
ip 
Continuo
us (C1) 
45J/cm2 
Continuo
us  (C2): 
30  J/cm2 
Fractiona
ted (F) 
(2min on, 
1min off) 
30  J/cm2 
HAL 
100mg/k
g ip 
Green F (n=16) vs. C1 (n=20) vs. C2 (n=20): 
Depth of necrosis ( µm ) thickness: 
213±113 vs.154±133 vs. 171±155, p <0.05 
Mean necrosis value (0-4): 
3.2±0.95 vs 2.2±1 vs. 2.55±1.19 
Responders (NV=3 or 4): 
75% (intermittent) vs. 40% (C1&C2) 
p<0.0001 
Full thickness necrosis (NV=4): 
50% vs. 10%, vs. 30%, p<0.0001 
Zohng 
2009 12  
USA 
Mice, 
Ovarian  
(OVCAR5) 
BPD-MA 0.25 
mg/kg i.p 
25 J/cm2 Single,  
90min  
690nm Mean percentage tumour re-growth (day 
5 post PDT): 
PDT (n=3) < control (n=4): -58% reduction 
vs. +59% increase, p<0.05.  
Ascencio 
2008 b13 
Rats Ovary 
(NuTu-19) 
HAL 100mg/kg 
ip 
Continuo
us  (C2): 
30  J/cm2 
 
Fractiona
ted (F) 
(2min on, 
1min off) 
30  J/cm2 
HAL 
100mg/k
g ip 
Green Necrosis value (0-4): 
C2 (n=20) vs. F (n=16): 
3.10±0.94 vs. 3.67±0.70, p < 0.05 
Ascencio 
2008a 14 
France 
Rats Ovary 
(NuTu-19) 
HAL 100mg/kg 
ip 
45 J/cm2 4 h Green Necrosis value (0-4): 
PDT vs. control: 3.35±1.01 vs. 0.35±0.63, 
p<0.05. 
Complete response (NV 3 or 4): 
PDT vs. control: 77% vs. 0% 
Ascencio 
200715 
France 
Rats Ovary 
(NuTu-19) 
5-ALA 60mg/kg 
i.p 
100J/cm2 
150J/cm2 
4 h  
Red 
 
 
Necrosis value (0-4): 
1.89±1.05 
2.67±1.00 
   30 J/cm2 
45 J/cm2 
 Green 3.22 ± 0.83  
1.89 ±0.93 
No necrosis in control (laser alone) group 
30 
 
 
del 
Carmen 
2005 16 
USA 
Mice 
Ovary  
(NIH:OVCA
R-5) 
BPD-MA 
0.25 mg/kg i.p  
20 J/cm2 1.5  Red  Mean % tumour burden:  
PDT (n=16) vs. control (n=11) 
38.2%, 95% CI 29.3%-47%, p< 0.001 
Molpus 
200017 
USA 
Mice 
Ovary  
(NIH:OVCA
R-5) 
Ce6-OC125 
(PIC) 
1mg/kg i.p 
25 J/cm2 3 Red Mean residual tumour (mg): 
Cationic PIC vs. anionic PIC vs. Ce6 vs. 
control: 
33±20 vs. 73±29 vs. 59±18 vs. 330±109 mg 
Lilge 1998 
18
 
USA 
Mice ovary 
( 
NIH:OVCA
R-5) 
BPD-MA 0.25 
mg/kg i.p 
15 J 1.25 (3 
courses 
at 72 h 
interval) 
Red Post PDT tumour burden: 
PDT (G1,2,3) vs. control: 138 vs.400  µg 
Molpus  
1996 19 
USA 
Mice 
Ovary  
(NIH:OVCA
R-5) 
BPD-MA  
0.25-2.0 mg/kg 
i.p  
20 J/cm2 1.5 (3 
courses 
at 72 h 
interval) 
Red  Mean weight of residual carcinoma at 
necropsy: 
PDT vs. control : 34.3±14 vs. 379±65 µg, 
p<0.001 
 
Animals with deposits >1mm at gross 
dissection: 
PDT vs. control: 27% vs. 100%. 
*Luc= luciferases expressing cancer cells. Tra-IR700= IR Dye 700 DX NHS ester conjugated to trastuzumab (anti-HER2), 
Ad/HER2-ECD= adenovirus transducing HER-2 extracellular domain gene into HER-2 negative gastric cancer cells, GSA-
IR700= *DODFWRV\O VHUXP DOEXPLQ ELQGV WR ȕ-D-galactose receptors. BLI= Bioluminescence Imaging assesses luciferase 
activity, NIR= near infra-red, ICGm= indocyanine green loaded lactosomes, ICGs= indocyanine green solution, 5-ALA= 
aminolevulinic acid, HAL= hexaminolaevulinate, BPD-MA= benzoporphyrin derivative-mono acid, Ce6-OC125= Chlorin e6 
conjugated with OC125, PIC= Photoimmunoconjugate, ePCI= Experimental Peritoneal Cancer Index. 
